Circulating Tumor DNA Minimal Residual Disease Detection of Non–Small-Cell Lung Cancer Treated with Curative Intent

Bruna Pellini, Aadel A. Chaudhuri

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations

Abstract

Circulating tumor DNA (ctDNA) minimal residual disease (MRD) is a powerful biomarker with the potential to improve survival outcomes for non–small-cell lung cancer (NSCLC). Multiple groups have shown the ability to detect MRD following curative-intent NSCLC treatment using next-generation sequencing–based assays of plasma cell-free DNA. These studies have been modest in size, largely retrospective, and without thorough prospective clinical validation. Still, when restricting measurement to the first post-treatment timepoint to assess the clinical performance of ctDNA MRD detection, they have demonstrated sensitivity for predicting disease relapse ranging between 36% and 100%, and specificity ranging between 71% and 100%. When considering all post-treatment follow-up timepoints (surveillance), including those beyond the initial post-treatment measurement, these assays’ performances improve with sensitivity and specificity for identifying relapse ranging from 82% to 100% and 70% to 100%, respectively. In this manuscript, we review the evidence available to date regarding ctDNA MRD detection in patients with NSCLC undergoing curative-intent treatment and the ongoing prospective studies involving ctDNA MRD detection in this patient population.

Original languageEnglish
Pages (from-to)567-575
Number of pages9
JournalJournal of Clinical Oncology
Volume40
Issue number6
DOIs
StatePublished - Feb 20 2022

Fingerprint

Dive into the research topics of 'Circulating Tumor DNA Minimal Residual Disease Detection of Non–Small-Cell Lung Cancer Treated with Curative Intent'. Together they form a unique fingerprint.

Cite this